Jefferies Sees Nearly 100% Upside in Synta Pharma. (SNTA)

June 25, 2012 8:02 AM EDT Send to a Friend
Get Alerts SNTA Hot Sheet
Price: $2.80 -2.1%

Rating Summary:
    7 Buy, 0 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade SNTA Now!
Join SI Premium – FREE
Jefferies doubled its price target on Synta Pharma. (NASDAQ: SNTA) from $7 to $14 ahead of GALAXY Interim Data.

The firm comments, "Top-line data from the GALAXY lung cancer Phase 2b interim analysis is expected this week, including activity observed in 2 subgroups which we believe to be mutant KRAS and high LDH. For progression-free survival at the interim to be statistically significant, we calculate ganetespib+docetaxel would need to show at least a 55% reduction in risk of progression, which we would see as a highly robust improvement in second-line lung cancer."

For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.

Shares of Synta Pharma. closed at $7.24 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, FDA, Hot Comments

Related Entities

Jefferies & Co

Add Your Comment